{"id":"pixantrone-cyclophosphamide-vincristine-rituximab-prednisone","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"10-20%","effect":"Infection"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-15%","effect":"Nausea"},{"rate":"5-15%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Pixantrone works by intercalating DNA strands, which prevents the enzyme topoisomerase II from unwinding DNA, ultimately leading to cell death. This mechanism is similar to other anthracyclines, but pixantrone has a more favorable side effect profile due to its reduced cardiotoxicity. Cyclophosphamide is an alkylating agent that adds an alkyl group to DNA, causing cross-linking and DNA damage, which triggers cell death. Vincristine is a vinca alkaloid that binds to tubulin, preventing microtubule formation and disrupting cell division. Rituximab is a monoclonal antibody that targets CD20 on B cells, leading to their depletion. Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation.","oneSentence":"Pixantrone is a synthetic anthracenedione that intercalates DNA, thereby inhibiting DNA replication and transcription.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:26:20.171Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory diffuse large B-cell lymphoma"},{"name":"Multiple myeloma"}]},"trialDetails":[{"nctId":"NCT00268853","phase":"PHASE2","title":"A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2005-11","conditions":"Diffuse Large-Cell Lymphoma","enrollment":124},{"nctId":"NCT00088530","phase":"PHASE3","title":"BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2004-07","conditions":"Lymphoma, Non-Hodgkin","enrollment":140}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BBR2778"],"phase":"phase_3","status":"active","brandName":"pixantrone, cyclophosphamide, vincristine, rituximab, prednisone","genericName":"pixantrone, cyclophosphamide, vincristine, rituximab, prednisone","companyName":"CTI BioPharma","companyId":"cti-biopharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pixantrone is a synthetic anthracenedione that intercalates DNA, thereby inhibiting DNA replication and transcription. Used for Relapsed or refractory diffuse large B-cell lymphoma, Multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}